CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR T- cell therapy: A promising novel approach for treatment of cancer.
CAR T- cell therapy: A promising novel approach for treatment of cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是一种有前景的新型癌症治疗方法,已成功用于某些癌症。其疗效尤见于某些白血病和淋巴瘤等血液系统恶性肿瘤,为治疗选择有限的患者带来希望。本综述介绍CAR-T 疗法在肿瘤学中的重要性、发展历史、CAR-T 工程和开发的近期创新、作用机制、毒性、临床试验及持续开展的研究。CAR-T 疗法有效应用的障碍包括抗原逃逸、肿瘤异质性、肿瘤微环境、靶向肿瘤外组织毒性、抗肿瘤活性有限及肿瘤浸润不足。本文还讨论CAR-T 疗法的全球监管、监管协调面临的挑战、FDA批准的CAR-T 疗法、临床应用、临床试验与研究,以及未来前景。
Chimeric Antigen Receptor T-cell (CAR-T cell) therapy is a promising cancer treatment that has shown success in treating certain type of cancer. It has demonstrated remarkable efficacy, particularly in hematologic malignancies such as certain types of leukemia and lymphomas, offering hope for patients with limited options. In this review the authors highlighted the importance of CAR-T cell therapy in oncology, history, recent innovations in CAR-T cell engineering and development, mechanism of action, toxic effects, clinical trials and ongoing research on CAR-T cell therapy.
Barriers to effective CAR-T cell therapy includes antigen escape, tumor heterogeneity, microenvironment of the tumor, On target, Off tumor toxicity, modest anti-tumor activity and limited tumor infiltration. In this review we discussed global regulations of CAR-T cell therapies, challenges of harmonized regulations, FDA approved CAR-T cell therapies, clinical applications, clinical trials and research and future prospects of CAR-T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。